NESS-040C5

NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB₂ receptor subtype, having a CB₂ affinity of 0.4nM, and 25x selectivity over the related CB₁ receptor.[2]

NESS-040C5

Clinical data
ATC code	none
Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
CAS Number	1445751-90-5
CompTox Dashboard (EPA)	DTXSID201010004
Chemical and physical data
Formula	C27H33N3OS
Molar mass	447.64 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2

See also

• AB-FUBINACA
• NESS-0327
• SR-144,528

References

1. Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
2. Hanus LO, Mechoulam R. "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.